Tianjin Chase Sun Jiandakang Medical Technology Co., Ltd. (the Company) formally opened at Binhai New Area. In the meanwhile, the Company introduced antineoplastic Class I new drug PTS and the industrialized projects of such drug’s derivative results to the new area. It also signed a cooperation agreement with the relevant department of Binhai New Area. He Lifeng, deputy secretary of the Party Committee of Tianjin Municipality and secretary of the Party Committee of Binhai New Area met with Zhong Nanshan, academician of the Chinese Academy of Engineering and superintendent of Guangzhou Institute of Respiratory Disease, and his delegation. Mr. He firstly extended greetings to the guests, congratulated them on the establishment of the Company, and then had a conversation with them about the further cooperation between both parties. Mr. He also conferred the Binhai New Area Technology Consultant Engagement Letter to Mr. Zhong Nanshan. Li Weicheng, a member of the standing Committee and secretary general of the Party Committee of Binhai New Area was presented at the meeting and Guo Jingping, deputy governor of Binhai New Area conducted the meeting. Besides, responsible persons from relevant departments of Tianjin Municipality and Binhai New Area as well as from the Management Committee of TEDA also attended the meeting.
He Lifeng said, “As an important national development strategy, Binhai New Area has been maintaining a good and fast momentum in economic society development for years; biomedicine industry is one of its eight leading advantageous industries and has gathered numerous biomedical enterprises renowned at home and abroad and pioneering talents to settle here, which have formed a batch of industrialized bases. Currently, we are busy increasing the financial input, optimizing investment environment and setting up carrier platforms, so as to solve the problem of “being independent from each other” between the economy and the technology and to promote the marketization of technological achievements. We both parties should take the settlement of this project as a chance, give full play to our own advantages, advance in a pioneering spirit, so as to obtain more remarkable cooperation achievements. Binhai New Area will continue providing high-quality “nanny-like” service and creating favorable conditions for the development of enterprises.”
Zhong Nanshan said, “Binhai New Area is an import biomedicine industrial base, in particular, it has smooth system and mechanism and encourages innovation vigorously, which must leads to a promising future. It is hoped that both parties could move forward to deepen our cooperation, quicken the step of project construction, and make concerted effort in promoting the biomedicine industry of Binhai New Area to achieve more glorious development.
Tianjin Chase Sun Jiangdakang Medical Technology Co., Ltd. was registered at Tianjin Economic & Technological Development Area and co-established by Tianjin Chase Sun Pharmaceutical Co., Ltd. and Beijing Jiandakang New Drug Development Co., Ltd. In the future, the Company will introduce antineoplastic Class I new drug PTS and the industrialized project of such drugs’ derivative results to Binhai New Area. Drug PTS is the first Class I antineoplastic new drug in China which is injected inside the tumor and with characteristics of high efficacy, broad spectrum, low toxicity and specificity recognition and staining. Currently, it is under the reporting stage of product registration certificate. As soon as the drug comes into the market, it is expected to reach an industrial scale of RMB 1 to 1.5 billion yuan and achieve profit and tax of RMB 300 to 400 million yuan within three years.
